Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kambayashi, Yumi, Ohuchi, Kentaro, Chiba, Hiromu, Tamabuchi, Erika, Nagasawa, Tasuku, Asano, Yoshihide, Fujimura, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149537/
https://www.ncbi.nlm.nih.gov/pubmed/35702675
http://dx.doi.org/10.1159/000524013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149537/
https://www.ncbi.nlm.nih.gov/pubmed/35702675
http://dx.doi.org/10.1159/000524013

Ejemplares similares